Under the scientific direction of Prof. Dr. David M. Leistner (Charité Universitätsmedizin Berlin) and in collaboration with Sahajanand Medical Technologies (SMT) Germany GmbH, IHF initiated the CRUZ-SENIOR study, a registry study to evaluate the safety and efficacy of the SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent system in the treatment of an octo- and nonagenarian all-comer patient cohort with coronary artery disease. This is a prospective, multi-centre, open, single-arm and non-interventional study to evaluate the results of the SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent system in an aged (?80 years) real-life patient cohort representing a significant most complex high-risk patient cohort for percutaneous coronary intervention (PCI) in daily routine. Furthermore, for the first time a prospective evaluation of different geriatric frailty measurements for risk stratification of very elderly patients undergoing percutaneous coronary intervention shall be performed. With the objective of enrolling 2000 patients at 37 clinical centers in Germany, Switzerland and Austria, this is the largest study project ever conducted on the SUPRAFLEX CRUZ™ Sirolimus-eluting coronary stent system. It is therefore a special project for all parties involved and the IHF is very pleased to accompany this registry. The inclusion of the first patient is planned for q1 /2021 and the entire study team is very dedicated to achieving this milestone.